Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The incidence of type 1 diabetes is rising worldwide, particularly in young children. Since type 1 diabetes is preceded by autoimmunity to islet antigens, there must be a consequent increase in the incidence of islet autoimmunity in young children or a more rapid rate of progression to diabetes once islet autoimmunity initiates. This study was to determine whether the incidence of islet autoimmunity or the rate of progression from autoimmunity to diabetes onset has changed over a 20-year period in children genetically predisposed to type 1 diabetes. Between 1989 and 2010, children who were first-degree relatives of patients with type 1 diabetes and who were born in Germany were prospectively followed from birth without intervention. A total of 324 children (BABYDIAB study) born between 1989 and 2000 and 216 children (TEDDY study) born between 2004 and 2010 with matched HLA genotypes were recruited before age 3 months and included for analysis. Children were followed for the development of autoantibodies to insulin, GAD, and IA-2, and for progression to diabetes. The cumulative frequency of diabetes by age 4 years was 2.5% (95% CI 0.8–4.2%) in BABYDIAB children and 6.2% (95% CI 2.3–10.1%) in TEDDY children (p=0.03). The cumulative frequency of islet autoantibodies by age 4 years was similar in the children from both studies (11.3% vs 13.9%). Progression to diabetes from the development of islet autoantibodies was markedly increased in autoantibody-positive children from the more recently recruited TEDDY cohort (50% progression within 85.2 months for BABYDIAB children vs 9.6 months for TEDDY children; p=0.009), also if children were further selected on the basis of high-risk HLA genotypes or the development of autoantibodies to multiple islet antigens (p=0.01). The findings suggest that recent increasing incidence of type 1 diabetes in young children could be due to weakening of mechanisms that normally regulate autoimmune destruction of islet beta cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patterson, C. C., Dahlquist, G. G., Gyürüs, E., Green, A., & Soltész, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60568-7 · Cited by 1,854 · cited 4×
“For TEDDY samples, measurement was performed in the central European laboratory in Bristol and when positive also in the US central laboratory in Denver.”
InfluentialIncidence of diabetes in youth in the United States
SEARCH for Diabetes in Youth Study Group*, T. W. G. F. T. (2007) · JAMA · doi:10.1001/jama.297.24.2716 · Cited by 991 · cited 1×
“Because of the high escalating increase in young children the formerly described peak T1D incidence around puberty [4] is no longer pronounced and we are starting to observe a constant incidence from age 1 year to 15 years of age [3].”
Prediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346 · cited 1×
“Check points in the pre-clinical pathogenesis include the initiation of islet autoimmunity measured by islet autoantibodies directed against insulin, glutamic acid decarboxylase (GAD), insulinoma-associated protein 2 (IA-2), and zinc transporter 8 (ZnT8), the spreading of the first islet autoantibody reactivity to mul…”
Self-citationBonifacio, E., Yu, L., Williams, A. K., Eisenbarth, G. S., Bingley, P. J., Marcovina, S. M., Adler, K., Ziegler, A. G., Mueller, P. W., Schatz, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0293 · Cited by 291
Self-citationTörn, C., Mueller, P. W., Schlosser, M., Bonifacio, E., Bingley, P. J., & Laboratories, P. (2008) · Diabetologia · doi:10.1007/s00125-008-0967-2 · Cited by 284 · cited 1×
“The three laboratories use similar IAA, GADA and IA-2A assays and have been shown to have similar sensitivity and specificity in the Diabetes Autoantibody Standardization Program (DASP) workshops [11,12], and for GADA and IA-2A also in NIDDK harmonization activities [13].”
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260 · cited 1×
“In contrast to the TEDDY children, but similar to progression rates in previous studies [7,15,17,18], 50% progression to diabetes in the antibody-positive BABYDIAB children was 85 months (p 1⁄4 0.”
Self-citationGrijse, D. (2010) · doi:10.1007/s00125-009-1618-y · Cited by 94
Cited by
Type 1 diabetes—early life origins and changing epidemiology
Norris, J. M., Johnson, R. K., & Stene, L. C. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30412-7 · Cited by 367
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Increasing Incidence of Type 1 Diabetes in Youth
Lipman, T. H., Levitt Katz, L. E., Ratcliffe, S. J., Murphy, K. M., Aguilar, A., Rezvani, I., Howe, C. J., Fadia, S., & Suarez, E. (2013) · Diabetes Care · doi:10.2337/dc12-0767 · Cited by 116
“The rate of progression from autoimmunity to onset of diabetes over the last 20 years was studied by Ziegler and colleagues (20).”
BackgroundChanging the landscape for type 1 diabetes: the first step to prevention
Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32127-0 · Cited by 96
Achenbach, P., Hummel, M., Thümer, L., Boerschmann, H., Höfelmann, D., & Ziegler, A. G. (2013) · Diabetologia · doi:10.1007/s00125-013-2896-y · Cited by 76
“The rate of progression from islet autoantibody seroconversion to type 1 diabetes varies considerably between individuals, ranging from a few months to many years [4–6], and recent data from Germany suggest that it has been accelerating over the last 20 years [7].”
BackgroundSelf-citation
Metadata
- Authors
- Ziegler, A.-G., Pflueger, M., Winkler, C., Achenbach, P., Akolkar, B., Krischer, J. P., & Bonifacio, E.
- Venue
- Journal of Autoimmunity
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 37
- Issue
- 1
- Pages
- 3-7
- ISSN
- 0896-8411 (ISSN-L)
- OpenAlex
- W2107869122
- Cited by
- 81
- References
- 7
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. https://app.cochat.ai/papers/10.1016/j.jaut.2011.02.004
- The paper
- Ziegler, A.-G., Pflueger, M., Winkler, C., Achenbach, P., Akolkar, B., Krischer, J. P., & Bonifacio, E. (2011). Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. Journal of Autoimmunity. https://doi.org/10.1016/j.jaut.2011.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.